Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant.

Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant. Eur J Endocrinol. 2018 Jan 25;: Authors: Strasburger CJ, Mattsson AF, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK Abstract Pegvisomant monotherapy is effective and safe in treatment of acromegaly.1,2 However, some clinicians combine pegvisomant with somatostatin analogues(SSA) or dopamine agonist(DA).2,3 In this analysis of ACROSTUDY, a long-term non-interventional study, the use of combination regimens was evaluated. Based on their baseline treatment, 2043 patients were retrospectively categorized as: long-acting SSA combined with pegvisomant, "Combo SSA" 768 patients(38%); DA combined with pegvisomant, "Combo DA" 123(6%); Pegvisomant monotherapy, "Peg mono" 1128(55%).Treatment patterns changed over the 10 year period, with recent patients more likely to receive any combination(20% in 2003 vs. 54% in 2012). Combo SSA use varied widely among countries from 22% to 78%. Exposure periods of the three treatment modalities were defined from pegvisomant start until the last visit in ACROSTUDY; patients could switch treatment categories. At year 4, IGF-I was normal in 62% of Combo SSA, 63% of Combo DA and 65% of Peg mono groups. Pegvisomant was initiated as daily injections in 94% of patients in the Peg mono group, 66% of Combo SSA and 91% of Combo DA patients. During 6169 years of treatment exposure, 3424 adverse ...
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Tags: Eur J Endocrinol Source Type: research